Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY900014 PK and Glucodynamics in T1DM on Insulin Pump
NCT03056456Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours Following Single-wave Bolus and Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours Following Dual-wave Bolus. Started Feb 2017; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03056456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056456.